Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

3SBio to Commercialize Multiple Samsung Bioepis Biosimilars in China

publication date: Jan 8, 2019

3SBio, a Shenyang biopharma, will partner with Samsung Bioepis, a Samsung BioLogics-Biogen JV, to develop and commercialize multiple Bioepis biosimilars (including an Avastin biosimilar) in mainland China. Under the agreement, Samsung Bioepis will manufacture the biosimilars. It will also collaborate with 3SBio on clinical development, regulatory registration, and commercialization. 3SBio will provide an upfront payment and pay clinical/regulatory milestone payments to Samsung Bioepis. More details....

Stock Symbol: (HK: 1530)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.